ERIS vs LINCOLN: Stock Comparison
ERIS LIFESCIENCES is the larger company by market capitalisation. ERIS LIFESCIENCES shows a higher dividend yield and a higher net margin, while LINCOLN PHARMA shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ERIS leads 4; LINCOLN leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ERIS | LINCOLN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ERIS | LINCOLN |
|---|---|---|
| Live Price | ₹1,121.2 | ₹510.85 |
| Day Change | -1.33% | -0.72% |
| Volume | 29,717 | 61,149 |
| 52-Week High | ₹1,740 | ₹770 |
| 52-Week Low | ₹1,111.1 | ₹440 |
| Distance from 52W High | -35.56% | -33.66% |
Valuation
| Metric | ERIS | LINCOLN |
|---|---|---|
| Market Cap | ₹15,432 Cr | ₹1,023 Cr |
| P/E Ratio | 23.79x | 10.61x |
| P/B Ratio | 3.95x | 1.35x |
| EPS | ₹10.28 | ₹18.09 |
| Book Value | ₹281.12 | ₹378.25 |
| Dividend Yield | 0.64% | 0.35% |
Growth
| Metric | ERIS | LINCOLN |
|---|---|---|
| Revenue Growth (TTM YoY) | 7.1% | 11.4% |
| EPS Growth (TTM YoY) | 200% | 0.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | ERIS | LINCOLN |
|---|---|---|
| ROE | 7.64% | 11.6% |
| ROCE | 10.32% | 10.97% |
| Net Margin | 19.89% | 13.1% |
| Operating Margin | 29.73% | 17.38% |
| Debt to Equity | 0.65x | 0.01x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ERIS | LINCOLN |
|---|---|---|
| Promoter Holding | 54.14%▲ 0.22 pp | 49.78% |
| FII Holding | 5.75%▼ 0.64 pp | 4.6%▼ 0.59 pp |
| DII Holding | 20.72%▲ 0.37 pp | 0.27%▼ 0.82 pp |
| Public Holding | 19.4%▲ 0.07 pp | 45.36%▲ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ERIS LIFESCIENCES and LINCOLN PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.